Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2018-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Abnormally Fertilized Embryos
NCT06940973
Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst?
NCT05837325
Study of the Best Blastocyst Post Transfer by aCGH
NCT01664546
PGT-A Versus Blastocyst Morphology Selection
NCT03095053
Comparative Study to Assess the Ongoing Pregnancy Rate for Poor Responders Women Undergoing Different Embryo Transfer Protocols
NCT05014867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMH < 0.5 ng/ml
preimplantation genetic test for aneuploidies (PGT-a)
preimplantation genetic test for embryo aneuploidies after IVF
AMH 0.5-0.99 ng/ml
preimplantation genetic test for aneuploidies (PGT-a)
preimplantation genetic test for embryo aneuploidies after IVF
AMH 1.0-1.49 ng/ml
preimplantation genetic test for aneuploidies (PGT-a)
preimplantation genetic test for embryo aneuploidies after IVF
AMH 1.5-1.99 ng/ml
preimplantation genetic test for aneuploidies (PGT-a)
preimplantation genetic test for embryo aneuploidies after IVF
AMH 2.0-4.99 ng/ml
preimplantation genetic test for aneuploidies (PGT-a)
preimplantation genetic test for embryo aneuploidies after IVF
AMH > 5.0 ng/ml
preimplantation genetic test for aneuploidies (PGT-a)
preimplantation genetic test for embryo aneuploidies after IVF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
preimplantation genetic test for aneuploidies (PGT-a)
preimplantation genetic test for embryo aneuploidies after IVF
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinica de la Mujer Medicina Reproductiva, Chile
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jose Antonio Moreno
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinica de la Mujer Medicina Reproductiva
Viña del Mar, Región de Valparaíso, Chile
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMH 2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.